

International Nonproprietary Names for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances,¹ notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, e.g., for List 62 Prop. INN not later than 31 May 1990.

The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.

Action and Use

The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded proposed INN. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature these descriptors will be neither revised nor included in the Cumulative Lists of INN.

Proposed International Nonproprietary Names (Prop. INN): List 62²

Comprehensive information on the INN programme can be found in WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances*; twentieth report of the WHO Expert Committee), ISBN 92 4 120581 4 (price: Sw. fr. 6.-) an account of this publication will be found in Annex 2 of the present List. All names from Lists 1-58 of Proposed International Nonproprietary Names, together with a molecular formula index, will be found in *International Nonproprietary Names (INN) for Pharmaceutical Substances: Cumulative List No. 7, 1988*, World Health Organization, Geneva (ISBN 92 4 0560149) (price: Sw. fr. 65.-). This publication consists, in the main, of a computer printout which groups together all the proposed and recommended international nonproprietary names (INN)—in Latin, English, French, Russian, and Spanish—published up to March 1988. The printout also indicates in which of the 58 individual lists of proposed names and 27 lists of recommended names each INN was originally published, and gives references to national nonproprietary names, pharmacopoeia monographs, and other sources. In addition, the list contains molecular formulae and Chemical Abstracts Service registry numbers. For easy reference, national nonproprietary names that differ from INN, molecular formulae, and Chemical Abstracts Service registry numbers are indexed in a series of annexes. A final annex describes the procedure for selecting recommended INN and outlines the general principles to be followed in devising these names. All the textual material published in this volume appears in both English and French.

These publications may be obtained, direct or through booksellers, from the sales agents listed on the back cover of *WHO Drug Information*. Orders from countries where sales agents have not yet been appointed may be addressed to: World Health Organization, Distribution and Sales Service, 1211 Geneva 27, Switzerland.

¹ Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld Hlth Org.*, 1955, 60, 3) and amended by the Board in resolution EB43.R9 (*Off. Rec. Wld. Hlth Org.*, 1969, 173, 10)


² Other lists of proposed and recommended international nonproprietary names can be found in *Cumulative List No. 7, 1988*.

Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


acidum risedronicum
risedronic acid

[1-hydroxy-2-(3-pyridyl)ethylidene]diphosphonic acid
 $C_7H_{11}NO_7P_2$ 105462-24-6 calcium regulator




actaritum
actarit

(*p*-acetamidophenyl)acetic acid
 $C_{10}H_{11}NO_3$ 18699-02-0 immunomodulator




aloracetamum
aloracetam

N[2-(3-formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide
 $C_{11}H_{16}N_2O_2$ 119610-26-3 nootropic agent




alprafenonum
alprafenone

(±)-3-[3-[2-hydroxy-3-(*tert*-pentylamino)propoxy]-4-methoxyphenyl]-4'-methoxypropiphenone
 $C_{25}H_{35}NO_4$ 124316-02-5 antidysrhythmic



ataprostum
ataprost

(+)-(2*E*,3*aS*,4*R*,5*R*,6*aS*)-4-[(1*E*,3*S*)-3-cyclopentyl-3-hydroxypropenyl]-3,3*a*,4,5,6,6*a*-hexahydro-5-hydroxy-Δ^{2(1*H*),5*S*}-pentalenevaleric acid
 $C_{21}H_{32}O_4$ 83997-19-7 platelet aggregation inhibitor




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use

batoprazinum
batoprazine

8-(1-piperazinyl)coumarin
 $C_{13}H_{14}N_2O_2$ 105685-11-8


psychotropic



brifentanilum
brifentanil

cis-N-[1-[2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-3-methyl-4-piperidyl]-2'-
fluoro-2-methoxyacetanilide
 $C_{20}H_{29}FN_5O_3$ 101345-71-5


narcotic analgesic



butenafinum
butenafine

N-(*p*-*tert*-butylbenzyl)-*N*-methyl-1-naphthalenemethylamine
 $C_{23}H_{27}N$ 101828-21-1


antifungal



candoxatrilatum
candoxatrilat

(*αS*)-1-[(*cis*-4-carboxycyclohexyl)carbamoyl]-*α*-[(2-methoxyethoxy)methyl]-
cyclopentanepropionic acid
 $C_{20}H_{33}NO_7$ 123122-54-3

antihypertensive




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


candoxatrilum
candoxatriil

(*α*S)-1-[(*cis*-4-carboxycyclohexyl)carbamoyl]-*α*-[(2-methoxyethoxy)methyl]cyclopentanepropionic acid, *α*-5-indanyl ester
C₂₉H₄₁NO₇ 123122-55-4 *antihypertensive*




cericlaminum
cericlamine

(±)-3-(3,4-dichlorophenyl)-2-(dimethylamino)-2-methyl-1-propanol
C₁₂H₁₇Cl₂NO 112922-55-1 *antidepressant*




ciclesonidum
ciclesonide

11 β ,16 α ,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
C₃₂H₄₄O₇ *glucocorticosteroid*



daniquidonum
daniquidone

8-aminoisoindolo[1,2-*b*]quinazolin-12(10*H*)-one
C₁₅H₁₁N₃O 67199-66-0 *antineoplastic*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


dapropterinum
dapropterin

(-)-(6*R*)-2-amino-6-[(1*R*,2*S*)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(3*H*)-
pteridinone
 $C_9H_{15}N_5O_3$ 62989-33-7 *antihyperphenylalaninaemic*




desfluranum
desflurane

(±)-difluoromethyl 1,2,2-tetrafluoroethyl ether
 $C_2H_2F_6O$ 57041-67-5 *general anaesthetic*




devazepidum
devazepide

(*S*)-*N*-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl)indole-
2-carboxamide
 $C_{25}H_{26}N_4O_2$ 103420-77-5 *cholecystokinin receptor antagonist*




dexrazoxanum
dexrazoxane

(+)-(*S*)-4,4'-propylenedi-2,6-piperazinedione
 $C_{11}H_{16}N_4O_4$ 24584-09-6 *antineoplastic*



ditekirenium
ditekiren

tert-butyl (2*S*)-2-[[[(*aS*)-α-[[[(1*S*)-1-[[[(1*S*,2*S*,4*S*)-2-hydroxy-1-isobutyl-5-methyl-
4-[[[(1*S*,2*S*)-2-methyl-1-[(2-pyridylmethyl)carbamoyl]butyl]carbamoyl]-
hexyl]carbamoyl]-2-imidazol-4-ylethyl)methylcarbamoyl]phenetyl]-
carbamoyl]-1-pyrrolidinecarboxylate
 $C_{50}H_{75}N_9O_8$ 103336-05-6 *renin inhibitor*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use

dosmalfatum
dosmalfate

$[\mu_8-[[\text{diosmin octasulfato}](8-)]\text{tetracontahydroxyhexadecaaluminum}$
 $\text{C}_{28}\text{H}_{64}\text{Al}_{16}\text{O}_{75}\text{S}_8$ 122312-55-4 *antacid*



duteplasmum
duteplase


245-L-methionineplasminogen activator (human tissue-type 2-chain form protein moiety)
 $\text{C}_{2736}\text{H}_{4174}\text{N}_{914}\text{O}_{824}\text{S}_{46}$ 120608-46-0 *thrombolytic*

ecogramostimum
ecogramostim

N-L-methionylcolony-stimulating factor 2 (human U937 cell protein moiety reduced)
123120-99-0 *immunostimulant*

elsamitrucinum
elsamitrucin

10-[[2-O-(2-amino-2,6-dideoxy-3-O-methyl- α -D-galactopyranosyl)-6-deoxy-3-O-methyl- β -D-galactopyranosyl]oxy]-6-hydroxy-1-methylbenzo[h][1]-benzopyrano[5,4,3-cde][1]benzopyran-5,12-dione
 $\text{C}_{33}\text{H}_{35}\text{NO}_{13}$ 97068-30-9 *antineoplastic*



epoetinum alfa
epoetin alfa

1-165-erythropoietin (human clone λ HEPOFL13 protein moiety)
 $\text{C}_{809}\text{H}_{1301}\text{N}_{229}\text{O}_{240}\text{S}_5$ 113427-24-0 *antianaemic*

epoetinum beta
epoetin beta


1-165-erythropoietin (human clone λ HEPOFL13 protein moiety), glycoform β
 $\text{C}_{809}\text{H}_{1301}\text{N}_{229}\text{O}_{240}\text{S}_5$ 122312-54-3 *antianaemic*

Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


eptastigminum
eptastigmine

N-demethyl-*N*-heptylphysostigmine or (3*a**S*,8*a**R*)-1,2,3,3*a*,8,8*a*-hexahydro-1,3*a*,8-trimethylpyrrolo[2,3-*b*]indol-5-yl heptylcarbamate
 $C_{21}H_{33}N_3O_2$ 101246-68-8 *acetylcholinesterase inhibitor*




pylotozinum
pylotozine

(+)-(*R*)- α -ethyl-*N,N*-dimethyl- α -[[(3,4,5-trimethoxybenzyl)oxy]methyl]benzylamine
 $C_{22}H_{31}NO_4$ 123618-00-8 *gastrointestinal agent*




finasteridum
finasteride

N-*tert*-butyl-3-oxo-4-aza-5 α -androst-1-ene-17 β -carboxamide
 $C_{23}H_{36}N_2O_2$ 98319-26-7 *antineoplastic*



fluvastatinum
fluvastatin

($\pm$)-(3*R**,5*S**,6*E*)-7-[3-(*p*-fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptenoic acid
 $C_{24}H_{26}FNO_4$ 93957-54-1 *antihyperlipidaemic*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


fosinoprilatum
fosinoprilat

(4S)-4-cyclohexyl-1-[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-L-proline
 $C_{23}H_{34}NO_5P$ 95399-71-6
angiotensin converting enzyme
inhibitor




fosphenytoinum
fosphenytoin

3-(hydroxymethyl)-5,5-diphenylhydantoin, dihydrogen phosphate (ester)
 $C_{16}H_{15}N_2O_6P$ 93390-81-9
antiepileptic




fosquidonum
fosquidone

benzyl 5,8,13,14-tetrahydro-14-methyl-8,13-dioxobenz[5,6]isoindolo-
[2,1-b]isoquinolin-9-yl hydrogen phosphate
 $C_{28}H_{22}NO_6P$ 114517-02-1
antineoplastic



gemcitabinum
gemcitabine

2'-deoxy-2', 2'-difluorocytidine
 $C_9H_{11}F_2N_3O_4$ 95058-81-4
antineoplastic




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


girisopamum
girisopam

1-(*m*-chlorophenyl)-7,8-dimethoxy-4-methyl-5*H*-2,3-benzodiazepine
C₁₈H₁₇ClN₂O₂ 82230-53-3 *anxiolytic*




glipalamidum
glipalamide

(±)-5-methyl-*N*-(*p*-tolylsulfonyl)-2-pyrazoline-1-carboxamide
C₁₂H₁₅N₃O₃S 37598-94-0 *antidiabetic*




ipazilidum
ipazilide

N-[3-(diethylamino)propyl]-4,5-diphenylpyrazole-1-acetamide
C₂₄H₃₀N₄O 115436-73-2 *antidysrhythmic*




isbufyllinum
isbufylline

7-isobutyltheophylline
C₁₁H₁₆N₄O₂ 90162-60-0 *antiasthmatic*



itrocinonidum
itrocinonide

6α,9-difluoro-11β,16α,17-trihydroxy-3-oxoandrosta-1,4-diene-17β-carboxylic acid, ester with ethyl (*S*)-1-hydroxyethyl carbonate, cyclic (*R*)-16,17-acetal with butyraldehyde
C₂₉H₃₈F₂O₉ 106033-96-9 *glucocorticosteroid*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


levemopamilum
levemopamil

(-)-(S)-2-isopropyl-5-(methylphenethylamino)-2-phenylvaleronitrile
 $C_{23}H_{30}N_2$ 101238-51-1 *calcium antagonist*




levetiracetamum
levetiracetam

(S)- α -ethyl-2-oxo-1-pyrrolidineacetamide
 $C_8H_{14}N_2O_2$ 102767-28-2 *nootropic agent*




lidanserinum
lidanserin

($\pm$)-4-[3-[4-(*p*-fluorobenzoyl)piperidino]propoxy]-4-methoxyphenyl]-
2-pyrrolidinone
 $C_{26}H_{31}FN_2O_4$ 73725-85-6 *serotonin antagonist*




lifibrolum
lifibrol

($\pm$)-*p*-[4-(*p*-*tert*-butylphenyl)-2-hydroxybutoxy]benzoic acid
 $C_{21}H_{26}O_4$ 96609-16-4 *antihyperlipidaemic*



melquinastum
melquinast

ethyl 6-ethyl-5,6-dihydro-9-methyl-5-oxo-*s*-triazolo[1,5-*c*]quinazoline-
2-carboxylate
 $C_{16}H_{16}N_4O_3$ 87611-28-7 *antiallergic*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


meribendanum
meribendan

4,5-dihydro-5-methyl-6-(2-pyrazol-3-yl-5-benzimidazolyl)-3(2*H*)-pyridazinone
 $C_{15}H_{14}N_6O$ 119322-27-9 *positive inotropic agent*




nardeterolum
nardeterol

(±)-α-[[[3-(1-benzimidazolyl)-1,1-dimethylpropyl]amino]methyl]-2-fluoro-4-hydroxybenzyl alcohol
 $C_{20}H_{24}FN_3O_2$ 73865-18-6 *β₂-adrenoreceptor agonist*




neltenexinum
neltexine

4',6'-dibromo-α-[(*trans*-4-hydroxycyclohexyl)amino]-2-thiophene-carboxy-*o*-toluidide
 $C_{18}H_{20}Br_2N_2O_2S$ 99453-84-6 *mutolytic*




napinalonum
napinalone

(±)-3,4-dihydro-1-methyl-1-(2-piperidinoethyl)-2(1*H*)-naphthalenone
 $C_{18}H_{25}NO$ 22443-11-4 *antitussive*



nitecaponum
nitecapone

3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione
 $C_{12}H_{11}NO_6$ 116313-94-1 *antiparkinson*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


oxilofrinum
oxilofrine

erythro-p-hydroxy- α -[1-(methylamino)ethyl]benzyl alcohol
 $C_{10}H_{13}NO_2$ 365-26-4
sympathomimetic




pancopridum
pancopride

($\pm$)-4-amino-5-chloro- α -cyclopropyl-N-3-quinuclidinyl- α -anisamide
 $C_{18}H_{24}ClN_3O_2$ 121650-80-4
antiemetic, anxiolytic




pantoprazolum
pantoprazole

5-(difluoromethoxy)-2-[[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-benzimidazole
 $C_{16}H_{13}F_2N_3O_4S$ 102625-70-7
antiulcer




pibaxizinum
pibaxizine

[2-[2-[4-(diphenylmethylene)piperidino]ethoxy]ethoxy]acetic acid
 $C_{24}H_{29}NO_4$ 82227-39-2
antispasmodic, antihistaminic



pilsicainidum
pilsicainide

tetrahydro-1*H*-pyrrolizine-7a(5*H*)-aceto-2',6'-xylidide
 $C_{17}H_{24}N_2O$ 88069-67-4
antidysrhythmic




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


quinagolidum
quinagolide

(±)-N,N-diethyl-N'-[(3*R**,4*aR**,10*aS**)-1,2,3,4,4*a*,5,10,10*a*-octahydro-6-hydroxy-1-propylbenzo[*g*]quinolin-3-yl]sulfamide
C₂₆H₃₃N₃O₃S 87056-78-8 *D*₂-dopamine receptor agonist




risotilidum
risotilide

4'-[isopropyl[2-(isopropylamino)ethyl]sulfamoyl]methanesulfonanilide
C₁₅H₂₇N₃O₄S₂ 120688-08-6 *antidysrhythmic*




rociclovirum
rociclovir

2-amino-9-[[2-isopropoxy-1-(isopropoxymethyl)ethoxy]methyl]purine
C₁₅H₂₅N₅O₃ 108436-80-2 *antiviral*




sampirtinum
sampirtine

2,6-diamino-3-(*p*-fluorobenzyl)pyridine
C₁₂H₁₂FN₃ 115911-28-9 *anti-inflammatory*



sarafloxacinum
sarafloxacin

6-fluoro-1-(*p*-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid
C₂₀H₁₇F₂N₃O₃ 98105-99-8 *antibacterial (vet.)*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


saviprazolum
saviprazole

2-[[[4-(2,2,3,3,4,4,4-heptafluorobutoxy)-2-pyridyl]methyl]sulfinyl]-1*H*-thieno[3,4-*d*]imidazole
 $C_{15}H_{10}F_7N_3O_2S_2$ 121617-11-6 *antiulcer*




secalciferolum
secalciferol

(5*Z*,7*E*,24*R*)-9,10-secocholesta-5,7,10(19)-triene-3 β ,24,25-triol
 $C_{27}H_{44}O_3$ 55721-11-4 *calcium regulator*




sezolamidum
sezolamide

(+)-(S)-5,6-dihydro-4-(isobutylamino)-4*H*-thieno[2,3-*b*]thiopyran-2-sulfonamide 7,7-dioxide
 $C_{11}H_{18}N_2O_4S_3$ 123308-22-5 *carbonic anhydrase inhibitor*



sobuzoxanum
sobuzoxane

4,4'-ethylenebis[1-(hydroxymethyl)-2,6-piperazinedione] bis(isobutyl carbonate) (ester)
 $C_{22}H_{34}N_4O_{10}$ 98631-95-9 *antineoplastic*



*Proposed International
Nonproprietary Name* (Latin, English)

*Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use*

somalaporum
somalapor


N-L-alanylgrowth hormone (pig clone pPGH-1 reduced)
 $C_{977}H_{1527}N_{265}O_{297}S_7$ 106282-98-8 *growth hormone*

somenoporum
somenopor

N-L-alanyl-32-de-L-glutamic acid-33-de-L-arginine-34-de-L-alanine-35-de-L-tyrosine-36-de-L-isoleucine-37-de-L-proline-38-de-L-glutamic acidgrowth hormone (pig clone pPGH-1 reduced)
 $C_{938}H_{1468}N_{255}O_{275}S_7$ 119693-74-2 *growth hormone*


timirdinum
timirdine

3-(2-amino-4-chlorophenyl)-2-iminothiazolidine
 $C_9H_{10}ClN_3S$ 100417-09-2 *antidepressant*




tiracizinum
tiracizine

ethyl 5-(*N,N*-dimethylglycyl)-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-3-carbamate
 $C_{21}H_{25}N_3O_3$ 83275-56-3 *antidysrhythmic*



trelnarizinum
trelnarizine

(*E*)-1-[bis(*p*-fluorophenyl)methyl]-4-(3,4-dimethoxycinnamyl)piperazine
 $C_{28}H_{30}F_2N_2O_2$ 123205-52-7 *vasodilator*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


tropisetronum
tropisetron

1 α H,5 α H-tropan-3 α -yl indole-3-carboxylate
C₁₇H₂₆N₂O₂ 89565-68-4 *serotonin antagonist*




vapreotidum
vapreotide

D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-tryptophanamide cyclic (2→7)-disulfide
C₅₇H₇₀N₁₂O₉S₂ 103222-11-3 *antineoplastic*



zatebradinum
zatebradine

3-[3-[(3,4-dimethoxyphenethyl)methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one
C₂₆H₃₆N₂O₅ 85175-67-3 *bradycardic agent*



Names for Radicals and Groups


Some substances for which a proposed international non-proprietary name has been established may be used in the form of salts or esters. The radicals or groups involved

may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals

and groups have been devised or selected, and they are suggested for use with the proposed international non-proprietary names.


bezomilum
bezomil

(benzoyloxy)methyl
 $C_8H_7O_2$



erbuminum
erbumine

tert-butylamine
 $C_4H_{11}N$



hyclas
hyclate

monohydrochloride hemiethanolate hemihydrate
 $\frac{1}{2}(C_2H_{10}Cl_2O_2)$

$\frac{1}{2}(2HCl \cdot C_2H_5OH \cdot H_2O)$

AMENDMENTS TO PREVIOUS LISTS

Chronicle of the World Health Organization, Vol. 12,
No. 3, 1958

Proposed International Nonproprietary Names (Prop. INN): List 6

- p 105 lauralkonii chloridum
lauralkonium chloride
- replace the chemical name by the following:*
benzyl[2-[p-(lauroyl)phenoxy]ethyl]dimethylammonium chloride

WHO Chronicle, Vol. 18, No. 11, 1964

Proposed International Nonproprietary Names (Prop. INN): List 14

- p 434 benzetimidum
benzetimide
- replace the CAS registry number by the following.*
119391-55-8

Supplement to WHO Chronicle, Vol. 38, No. 4, 1984

Proposed International Nonproprietary Names (Prop. INN): List 52

- p. 10 etomoxirum
etomoxir
- replace the chemical name by the following:*
(+)-ethoxi 2-[6-(p-chlorophenoxy)hexyl]glycidate

WHO Drug Information, Vol. 1, No. 3, 1987

Proposed International Nonproprietary Names (Prop. INN): List 58


- | | | |
|--------|--------------------------|--|
| p. 182 | isamoltanum
isamoltan | replace the CAS registry number by the following:
116861-00-8 |
|--------|--------------------------|--|

WHO Drug Information, Vol. 2, No. 2, 1988

Proposed International Nonproprietary Names (Prop. INN): List 59

- p. 9 manidipinum *replace the CAS number by the following:*
 manidipine 120092-68-4

- p. 9 mureoderminum
 mureodermin *replace the graphic formula by the following:*




- p 10 nebracetamum
nebracetam
-
replace the CAS number by the following:
116041-13-5

- p. 10 ondansetronum
ondansetron *replace the Chemical Abstracts Number by the following:*
116002-70-1

WHO Drug Information, Vol. 3, No. 2, 1989

Proposed International Nonproprietary Names (Prop. INN): List 61

- | | | |
|------------|--|---|
| p. 88 | bakeprofenum
bakeprofen | <i>replace the CAS registry number by the following:</i>
117819-25-7 |
| p. 89 | carmoxirolum
carmoxirole | <i>replace the action and use statement by the following.</i>
D ₂ -dopamine receptor agonist |
| p. 95 | gevotrolinum
evotroline | <i>replace the chemical name by the following:</i>
8-fluoro-2,3,4,5-tetrahydro-2-[3-(3-pyridyl)propyl]-1H-pyrindo[4,3-b]indole |
| p. 98 | natr. borocaptate (¹⁰ B)
sodium borocaptate (¹⁰ B) | <i>replace the molecular formula by the following</i>
¹⁰ B ₁₂ H ₁₂ Na ₂ S |
| - 105
| cefprozilum
cefprozil | <i>replace the graphic formula by the following:</i> |



Procedure and Guiding Principles

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will from now on be reproduced in uneven numbers of proposed INN lists only.